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Abstract 
Background: Autism spectrum disorder (ASD) has a high cost to affected individuals and society, but treatments for 
core symptoms are lacking. To expand intervention options, it is crucial to gain a better understanding of potential 
treatment targets, and their engagement, in the brain. For instance, the striatum (caudate, putamen, and nucleus 
accumbens) plays a central role during development and its (atypical) functional connectivity (FC) may contribute to 
multiple ASD symptoms. We have previously shown, in the adult autistic and neurotypical brain, the non-intoxicating 
cannabinoid cannabidivarin (CBDV) alters the balance of striatal ‘excitatory–inhibitory’ metabolites, which help regu-
late FC, but the effects of CBDV on (atypical) striatal FC are unknown.
Methods: To examine this in a small pilot study, we acquired resting state functional magnetic resonance imag-
ing data from 28 men (15 neurotypicals, 13 ASD) on two occasions in a repeated-measures, double-blind, placebo-
controlled study. We then used a seed-based approach to (1) compare striatal FC between groups and (2) examine 
the effect of pharmacological probing (600 mg CBDV/matched placebo) on atypical striatal FC in ASD. Visits were 
separated by at least 13 days to allow for drug washout.
Results: Compared to the neurotypicals, ASD individuals had lower FC between the ventral striatum and frontal 
and pericentral regions (which have been associated with emotion, motor, and vision processing). Further, they had 
higher intra-striatal FC and higher putamenal FC with temporal regions involved in speech and language. In ASD, 
CBDV reduced hyperconnectivity to the neurotypical level.
Limitations: Our findings should be considered in light of several methodological aspects, in particular our partici-
pant group (restricted to male adults), which limits the generalizability of our findings to the wider and heterogene-
ous ASD population.
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Background
Autism spectrum disorder (ASD) is a neurodevelop-
mental condition. Core symptoms of ASD include diffi-
culties across the domains of social communication and 
restricted and repetitive behaviours, and altered sen-
sory processing [1]. Additional transdiagnostic symp-
toms comprise, e.g. atypical motor [2], (social) reward 
[3], executive [4], mood, and emotion [5, 6] processing. 
Combined, these difficulties incur a high cost to affected 
individuals and society [7–9]. Nonetheless, there are cur-
rently no effective pharmacological treatments for the 
core symptoms of ASD, and conventional drug treatment 
of co-occurring difficulties is often unsatisfactory. To 
expand intervention options in ASD, it is crucial to gain a 
better understanding of potential brain targets and their 
engagement by putative treatments.
One potential target is the striatum, a basal ganglia 
structure comprising the caudate, putamen, and nucleus 
accumbens [10]. The striatum is functionally connected 
to widespread cortical domains and contributes to nearly 
every cognitive-behavioural function altered in ASD, 
such as social [11], motor [12], or reward [11] process-
ing. For instance, the caudate and accumbens connect 
with the cortex along a ventral-dorsal limbic-cognitive 
control axis [13], whereas putamenal functional connec-
tivity (FC) with cortex follows a rostral-caudal executive 
control-motor axis [13–15]. Also, the striatum serves a 
critical role throughout brain development. For example, 
a recent study in > 900 children and adults reported an 
association between (dys)maturation of striatal FC and 
pathophysiology in the general population [16]. This sug-
gests that striatal impairment may disturb neurodevel-
opment in general and contribute to conditions such as 
ASD.
Consistent with this, previous studies have reported 
multiple atypicalities of the striatum and its FC in ASD. 
These include, for example, an imbalance in the levels 
of excitatory glutamatergic and inhibitory GABAergic 
metabolites in children and adults [17–19]; hypoactiva-
tion during response-shifting [20] and social (reward) 
processing [21] (and the latter correlated with ASD 
symptom severity in adolescents [21]); and volumetric 
expansion of the caudate [22–24], which correlated with 
repetitive behaviour in adults [23]. Our previous work 
also found that volumetric expansions are present from 
at least as early as 6  months in infants at risk of devel-
oping ASD, and a larger striatum at this age predicted 
autistic symptoms and diagnosis at 36 months [25]. This 
highlights the relevance of the striatum in the pathophys-
iology of ASD and suggests that striatal pathology may 
be primary to ASD, rather than acquired as a secondary 
consequence of living with this condition.
Therefore, it is perhaps unsurprising that a wealth of 
research has found striatal FC to be altered in ASD, but 
the direction of findings varies considerably, with some 
striatal regions being hypoconnected and others being 
hyperconnected with the rest of the brain [26–30]. While 
the heterogeneous nature of participating cohorts likely 
contributes to frequent replication difficulties, previous 
studies have also relied primarily upon relatively ‘coarse’ 
definitions of the complex striatal circuitry. Thus, more 
fine-grained analyses are needed to dissect striatal FC 
differences in ASD and to test whether these constitute 
a biological target that can be ‘shifted’ pharmacologically 
in ASD.
Therefore, in the current study, we applied a detailed 
seed-based approach [13, 31, 32] to resting state func-
tional magnetic resonance imaging data with the aim of 
examining the FC of the striatum in autistic and neuro-
typical adults. Based on previous findings [26–30], we 
predicted a complex pattern of both striatal hyper- and 
hypoconnectivity with the rest of the brain in ASD rela-
tive to a neurotypical control group. Our second aim was 
to test whether (disrupted) striatal FC could be engaged 
by a candidate treatment. Promising candidates include 
non-intoxicating cannabinoids such as cannabidiva-
rin (CBDV). Emerging evidence suggests that CBDV 
acts on multiple neuroglial targets, which may effect a 
downstream modulation of the brain excitation–inhibi-
tion (E–I) balance, a crucial regulator of FC [33–35]. For 
instance, preclinical studies have shown that CBDV binds 
to several transient receptor potential (TRP) receptors 
(e.g. vanilloid type 1 (TRPV1), vanilloid type 2 (TRPV2), 
and ankyrin type 1 (TRPA1) [36]). These receptors have 
Conclusion: In conclusion, here we show atypical striatal FC with regions commonly associated with ASD symp-
toms. We further provide preliminary proof of concept that, in the adult autistic brain, acute CBDV administration can 
modulate atypical striatal circuitry towards neurotypical function. Future studies are required to determine whether 
modulation of striatal FC is associated with a change in ASD symptoms.
Trial registration: clinicaltrials.gov, Identifier: NCT03537950. Registered May 25th, 2018—Retrospectively registered, 
https:// clini caltr ials. gov/ ct2/ show/ NCT03 537950? term= NCT03 53795 0& draw= 2& rank=1.
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been identified on (sub)cortical excitatory and inhibitory 
neurons [37] and microglia [38], including in the striatum 
[39, 40]. Given the role of the striatum as a key neural 
hub, CBDV could alter excitatory and inhibitory neuro-
transmission—and hence striatal FC—directly through 
these striatal receptors and/or indirectly through action 
on interconnected regions. In line with this, we have pre-
viously demonstrated that a single dose of CBDV alters 
striatal levels of glutamate [18]. However, whether CBDV 
also shifts striatal FC remains to be investigated. Hence, 
here we examined and compared striatal FC in the adult 
autistic and neurotypical brain at baseline (placebo) and 




This research was conducted in accordance with the 
Declaration of Helsinki, at the Institute of Psychiatry, 
Psychology and Neuroscience at De Crespigny Park, 
SE5 8AF, London, UK (August 2016 to February 2017). 
The King’s College London Research Ethics Commit-
tee provided institutional ethical approval for this study 
(reference HR15/162744). The Medicines and Health 
Research Authority in the UK confirmed that our study 
design was not a clinical trial. Nonetheless, in the inter-
ests of transparency, we registered this experimental 
study on clinicaltrials.gov (identifier: NCT03537950, 
entry name: HR15-162744; Registered May 25th, 2018—
retrospectively registered, https:// clini caltr ials. gov/ ct2/ 
show/ NCT03 537950? term= NCT03 53795 0& draw= 2& 
rank=1). All participants provided written informed 
consent and took part in all aspects of this case–control 
observational study.
This project was a placebo-controlled, randomized, 
double-blind, repeated-measures, cross-over case–con-
trol study as part of a larger investigation into the role of 
phytocannabinoids in ASD; clinicaltrials.gov (identifier: 
NCT03537950, entry name: HR15-162744). Accordingly, 
the sample size was determined using power analyses to 
achieve sufficient power for this larger investigation [17]. 
Drugs were allocated in a pseudo-randomized order, so 
that each participant received each compound (placebo, 
PLC; cannabidivarin, CBDV) once. Approximately half 
of our participants received PLC first, and half CBDV. 
This randomization was implemented by G. M. M. using 
https:// www. random. org/. All participants attended for 
two visits, which were separated by at least 13  days to 
allow for drug wash-out (between-visit times were con-
sistent across visits and participants). Data acquisition 
from both groups occurred during the same time period. 
On each visit, participants received a brief health check, 
a liquid oral dose of the pharmacological probe (600 mg 
of CBDV; in line with previous single-dose studies of 
CBD in adults (e.g. [41]) or a matched placebo [base-
line], both provided by GW Research Ltd, Cambridge, 
UK), and a second brief health check to test for potential 
acute adverse reactions/side effects. Two hours after drug 
administration (at the time of peak plasma levels [Inves-
tigator’s brochure for CBDV, Edition 4, May 2016]), par-
ticipants underwent scanning, followed by a third health 
check to ensure that they experienced no ill effects and 
were fit to leave the department.
Participants
Potential participants were excluded if they had a 
comorbid major psychiatric or medical disorder affect-
ing brain development (e.g. schizophrenia or epilepsy), 
a history of head/brain injury, a genetic disorder associ-
ated with ASD (such as fragile X syndrome or tuberous 
sclerosis), or an IQ below 70. We also excluded partici-
pants if they were reliant on regular medication known 
to affect directly the glutamate and GABA neurotrans-
mitter systems, such as benzodiazepines, but included 
those on other medications frequently prescribed in 
ASD. Participants were asked to abstain from using 
cannabis and/or other illicit substances in the month 
prior and during the study, and from drinking alcohol 
on the days before visits. All participants in the ASD 
group had a clinical diagnosis of ASD made accord-
ing to ICD10 research criteria, supported by the use of 
standardized research diagnostic instruments (Autism 
Diagnostic Observation Schedule, ADOS; and Autism 
Diagnostic Interview-Revised, ADI-R) [42–44]. For 
more information, please refer to Table 1.
Image data acquisition
All imaging data were acquired on a 3  T GE Excite II 
magnetic resonance imaging (MRI) scanner (GE Medi-
cal Systems, Milwaukee, WI, USA). The scanning pro-
tocol included a structural MRI scan acquired using a 
3D inversion recovery prepared fast spoiled gradient 
recalled (IR-FSPGR) sequence (slice thickness = 1.1 mm, 
spatial positions = 124, flip angle = 20°, field of view 
(FoV) = 280  mm, echo time (TE) = 2.844  ms, repeti-
tion time (TR) = 7.068 ms, inversion time (TI) = 450 ms, 
matrix = 256 × 256). This structural MRI scan was used 
for co-registration of the functional volumes. The scan-
ning protocol also included a resting state MRI scan. This 
scan was acquired using an echo-planar imaging (EPI) 
sequence (slice thickness = 3 mm, slice gap = 3.3 mm, flip 
angle = 75°, FoV = 240  mm, TE = 30  ms, TR = 2000  ms, 
TI = 0 ms). We collected data for 256 time points, i.e. the 
resting state scan lasted 512 s.
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Data processing
All analyses were performed using in-house software, 
CONN v.18b [45] and MATLAB R2018b (The Math-
Works, Inc., MA, USA).
Structural data processing
All T1-weighted structural MRI scans were inspected 
manually to ensure adequate data quality and signal-to-
noise ratio and normalized to Montreal Neurological 
Institute (MNI) space. Next, all volumes were segmented 
into grey matter (GM), white matter (WM) and cerebro-
spinal fluid (CSF) to enable the removal of WM and CSF 
confounds using linear regression.
Resting state data processing
All T2-weighted resting state MRI scans were inspected 
manually to exclude data with obvious artefacts, e.g. 
blurring, distortions, ghosting, or warping.
We discarded the first five functional volumes to allow 
for magnetization equilibrium. Next, all remaining func-
tional volumes were slice-time corrected, realigned 
(first: within each subject, all 3D volumes [251 per sub-
ject] are aligned to that subject’s first 3D volume (within 
subject); second: all subjects’ 3D volumes are aligned 
to the first subject’s first 3D volume (across subjects)) 
and unwarped. We used ARtifact detection tools (ART) 
(https:// www. nitrc. org/ proje cts/ artif act_ detect/) to 
identify functional outliers (global signal z-value thresh-
old = 3 standard deviations and subject motion thresh-
old = 1 mm in line with previous studies, e.g. [46]). Next, 
we performed functional direct segmentation and nor-
malization to MNI space and smoothed our data using a 
Gaussian filter with a 6-mm full width at half maximum 
(FWHM) kernel. Importantly, head motion can distort 
measures of FC [47]. Therefore, when denoising our data, 
we not only excluded WM and CSF confounds, but also 
removed realignment and movement confounds (ART 
scrubbing and realignment parameters as well as their 
first-order derivatives) using linear regression. We then 
filtered (band-pass: 0.008–0.09) and detrended (linear 
trend removal) our data. We excluded all runs with move-
ment in any dimension ≥ 3 mm/° and/or ≥ 5% of volumes 
identified as motion outliers (frame-to-frame displace-
ment > 1 mm/° translation/rotation). This resulted in the 
exclusion of one run (CBDV) from one subject (ASD).
Next, we determined striatal seed regions. As these 
were based on previous literature and have been vali-
dated extensively [13], we followed the previous research 
approach used in ASD [32] of not customizing them to 
each individual. Further, given that cortico-striatal FC is 
known to be hemisphere specific in neurotypicals [48], 
and given the wealth of research indicating atypical lat-
eralization of FC in ASD [49, 50], we chose to examine 
seeds separately within each hemisphere rather than 
merging them. Consequently, our regions of interest 
included (bilateral) seeds in the caudate: the inferior ven-
tral striatum (Vsi; MNI coordinates: x =  ± 9, y = 9 z = -8), 
superior ventral striatum (VSs; ± 10 15 0), and dorsal cau-
date (DC; ± 13 15 9). They also included (bilateral) seeds 
in the putamen: the dorsal caudal putamen (dcP; ± 28 
1 3), dorsal rostral putamen (drP; ± 25 8 6), and ventral 
rostral putamen (vrP; ± 20 12 -3). In line with previous 
studies, each of these 12 seeds covered 33.5 voxels (4 mm 
radius in  2mm2 space). For more information on the seed 
placement, see Additional file 1: Figure S1.
Table 1 Participant demographics
Demographics (mean ± standard deviation [range])) and test statistic of between-group comparison
ADI autism diagnostic interview (com, communication domain; rep, restricted and repetitive behaviours domain), ADOS autism diagnostic observation schedule (com, 
communication domain; soc, social domain), AQ autism quotient, CBDV cannabidivarin, FSIQ full-scale intelligence quotient, PLC placebo, TV1–V2, time between visits 1 
and 2
a n = 10
Measure ASD (n = 13) Neurotypicals (n = 15) Test statistic
Age at visit 1 (years) 30.6 ± 11.2 [20–50] 28.5 ± 6.1 [21–40] F(1, 26) = 0.389, p = .538
ADI  coma 7.5 ± 5.0
ADI  repa 4.0 ± 2.6
ADOS com 4.4 ± 3.3
ADOS soc 7.6 ± 4.1
AQa 29.1 ± 13.7
FSIQ 113.0 ± 18.1 125.3 ± 12.7 F(1, 26) = 4.421, p = .045
TV1–V2 (days) 31.2 ± 17.9 28.1 ± 15.0 F(1, 26) = 0.248, p = .623
Mean motion (CBDV) 0.015 ± 0.067 0.008 ± 0.043 F(1, 26) = 0.100, p = .754
Mean motion (PLC) 0.014 ± 0.049 0.008 ± 0.050 F(1, 26) = 0.097, p = .758
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For each subject, we computed whole-brain voxel-
wise correlations for the mean time series of each of the 
12 seeds. Pearson’s correlation coefficients were Fisher-
transformed to improve normality of the data. Individual 
FC maps were then entered into standard analyses of var-
iance to evaluate experimental effects.
We only included participants in our repeated-meas-
ures analyses who retained scans for both the PLC and 
the CBDV condition; hence, our final sample included 28 
individuals (15 neurotypicals and 13 ASD).
Statistical analysis
Demographic measures (age, full-scale IQ, time between 
visits, head motion) were compared using a one-way 
ANOVA (significance level p < 0.05).
First, we tested for differences in baseline (PLC condi-
tion) striatal FC between groups using an ANOVA with 
group as the between-group factor. Given the exploratory 
nature of this pilot study, we did not correct for multi-
ple comparisons across the 12 seed regions. However, we 
recognize this is a point of debate and in the interest of 
transparency, we also include information about whether 
these effects would have survived highly stringent cor-
rection for multiple comparisons across six bilateral 
(0.05/6 = 0.008) and/or 12 individual (0.05/12 = 0.004) 
seeds.
Second, we examined whether between-group differ-
ences in baseline striatal FC were modulated by pharma-
cological probing. We used a repeated-measures ANOVA 
with group as the between-group factor and drug (PLC, 
CBDV) as the within-group factor, and corrected for 
multiple comparisons (0.05/3 = 0.017) across the three 
connections (cluster 1/target 1, cluster 1/target 2, cluster 
2/target 1) included in this analysis step. We also con-
ducted supplementary analyses to delineate baseline stri-
atal FC within each group using a one-sample t test. Due 
to the exploratory nature of our study, these results were 
not corrected across seeds.
Additionally, to account for multiple comparison cor-
rections, we thresholded our neuroimaging findings at 
voxel level (puncor < 0.001) and cluster level (pFDR < 0.05, 
cluster-size corr.) [51]. We provide effect sizes (Cohen’s 
d) based on degrees of freedom and T-values of average, 
group-level, connectivity values within each cluster.
Results
Demographics
Our final analysis included 28 individuals (15 neuro-
typicals and 13 ASD). Groups were matched for age, 
time between visits, and head motion during both drug 
conditions (all p ≥ 0.54). In contrast, and as is common 
in studies including participants with ASD, groups dif-
fered slightly in regard to full-scale IQ (F(1, 26) = 4.421, 
p = 0.045); specifically, individuals with ASD had slightly 
lower full-scale IQ (113.0 ± 18.1) than the neurotypical 
group (125.3 ± 12.7). For more information, please refer 
to Table 1.
Striatal FC at baseline and following CBDV
Next, we identified between-group differences in base-
line striatal FC and examined whether these were altered 
by CBDV. As expected, we observed both striatal hyper- 
and hypoconnectivity in ASD (Fig.  1, Additional file  1: 
Table  S1). This hyperconnectivity in ASD at baseline 
was shifted toward neurotypical (no differences between 
groups during CBDV) following pharmacological prob-
ing (Fig. 1, Additional file 1: Table S2). Last, we conducted 
supplementary analyses to delineate striatal baseline FC 
within each group separately, the results of which can be 
found in Figs. 2, 3 and Additional file 2: Tables S3–4. We 
observed spatially overlapping patterns of FC of groups 
(ASD vs TD) and hemispheric seeds (left vs right), as well 
as group- and hemisphere-specific spatial profiles.
R VSi: left anterior paracentral lobule/left anterior 
cingulate gyrus
Baseline FC between the R VSi and a cluster contain-
ing the left anterior paracentral lobule and left anterior 
cingulate gyrus was lower in the ASD group compared 
to the neurotypicals (pFDR = 0.0038, Cohen’s d = 2.42; 
this result was retained following multiple compari-
son correction across 6 bilateral/12 unilateral seeds). 
We observed a group-by-drug interaction effect on this 
connection (pFDR = 0.0148, d = 1.02; this result survived 
multiple comparison correction across connections). 
Post hoc testing indicated that, although CBDV some-
what increased FC in the ASD group, this effect was not 
statistically significant; in contrast, CBDV elicited a sta-
tistically significant decrease in FC in the neurotypicals 
(p = 0.0127, d = 1.53).
R VSi: left putamen
Baseline FC between the R VSi and the left putamen 
was greater in the ASD group compared to the neuro-
typicals (pFDR = 0.0178, d = 1.97; result not retained fol-
lowing multiple comparison correction across seeds). 
Again, we observed a significant group-by-drug interac-
tion effect on this functional connection (pFDR = 0.0086, 
d = 1.11; result survived multiple comparison correc-
tion across connections). Specifically, CBDV caused a 
statistically significant reduction in this FC in the ASD 
group (pFDR = 0.0476, d = 1.28), but had no effect in the 
neurotypicals.
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R vrP: right posterior superior temporal gyrus
Baseline FC between the R vrP and the right posterior 
superior temporal gyrus was greater in the ASD group 
compared to the neurotypicals (pFDR = 0.0050, d = 2.50; 
results retained following correction for six, but not 
12, seeds). We observed a group-by-drug interaction 
effect (pFDR = 0.0006, d = 1.52; result survived multi-
ple comparison correction across connections). Again, 
CBDV reduced FC in the ASD group (pFDR = 0.0170, 
Fig. 1 Striatal functional connectivity (FC) after placebo/drug administration. a, b Baseline between-group (ASD > neurotypicals) differences in FC 
of the right inferior ventral striatum (R VSi) and right ventral-rostral putamen (R vrP), respectively. Colourbars indicate T-values. Numbers above and 
below slices indicate Montreal Neurological Institute (MNI) z-coordinates. c–e: Group (ASD > neurotypicals) by drug (CBDV > PLC) interaction effects 
on atypical baseline striatal FC between the R VSi/R vrP and clusters identified above (MNI coordinates represent peak voxel locations). Graphs show 
average values per subject/cluster. FC functional connectivity (Fisher-transformed Pearson’s Correlation coefficients), L left, LH left hemisphere, PLC 
placebo, R right, RH right hemisphere, vrP ventral-rostral putamen, VSi inferior ventral striatum
Page 7 of 14Pretzsch et al. Molecular Autism           (2021) 12:49  
Fig. 2 Baseline striatal (caudate) functional connectivity within each participant group. Striatal (caudate) functional connectivity at placebo in the 
ASD group (blue), the neurotypicals (yellow), and the overlap of both groups (green). Numbers below slices indicate Montreal Neurological Institute 
(MNI) z-coordinates. DC dorsal caudate, LH left hemisphere, RH right hemisphere, VSi inferior ventral striatum, VSs superior ventral striatum
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Fig. 3 Baseline striatal (putamen) functional connectivity within each participant group. Striatal (putamen) functional connectivity at placebo in 
the ASD group (blue), the neurotypicals (yellow), and the overlap of both groups (green). Numbers below slices indicate Montreal Neurological 
Institute (MNI) z-coordinates. dcP dorsal-caudal putamen, drP dorsal-rostral putamen, LH left hemisphere, RH right hemisphere, vrP ventral-rostral 
putamen
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d = 1.60), but also increased it in the neurotypicals 
(pFDR = 0.0181, d = 1.43).
Discussion
Core and associated symptoms in ASD have been linked 
to atypicalities in the striatum and its functional circuitry. 
However, it remains unclear how exactly the striatum is 
functionally connected—and if its (atypical) FC can be 
shifted pharmacologically—in ASD. Here we investigated 
this in a small pilot study using a seed-based approach 
to resting state functional magnetic resonance imaging 
(rsfMRI) data. As expected, we found that, in ASD, the 
striatum displayed both hyper- and hypoconnectivity 
with numerous cortical regions; and that CBDV shifted 
atypical connections towards neurotypical findings at 
baseline.
Previous studies have used detailed seed-based 
approaches to examine striatal FC, for example, in neu-
rotypical adults [13] and autistic children [32]. Also, prior 
research has examined the effects of cannabinoids on 
striatal FC in both neurotypical and patient groups. For 
instance, CBD has been reported to increase striatal FC 
with the prefrontal cortex in neurotypicals at rest [52], 
reduce striatal-hippocampal FC in people with psychosis 
at rest [53], and increase striatal-frontal FC in occasional 
cannabis users during a visual oddball task [41]. Here, we 
extended this research to adults with ASD and to CBDV.
We found that the R VSi and the left putamen were 
hyperconnected in the ASD compared to the neuro-
typical group. This finding is similar to previous studies 
that reported local overconnectivity in ASD [54]. CBDV 
reduced this atypically strong intra-striatal FC in ASD, 
while exerting no effects on this connection in the neuro-
typicals. Similarly, baseline FC between the R vrP and the 
right posterior superior temporal gyrus was increased in 
ASD compared to the neurotypicals. Again, CBDV signif-
icantly reduced this hyperconnectivity in ASD. The right 
posterior superior temporal gyrus is thought to support 
hearing, speech, and language [55, 56]. Together with the 
vrP, it forms part of a cortico-striatal ‘associative/cogni-
tive’ loop. Hence, our findings are not only in line with 
previous studies in ASD showing disruptions in striatal-
temporal FC [32, 57], they also match reports of impair-
ments in associative and cognitive processing in this 
condition [58].
In contrast, we observed weaker FC in ASD relative 
to the neurotypicals between the R VSi and the left 
anterior paracentral lobule and left anterior cingulate 
gyrus. Although not statistically significant, qualitative 
inspection of the data (Fig.  1c) suggests that in ASD, 
CBDV tended to increase this FC towards the neuro-
typical pattern found at baseline. In the neurotypicals, 
on the other hand, this connection was significantly 
decreased by CBDV. The anterior paracentral lobule is 
implicated in vision and motor processing [59, 60]. It 
is traditionally thought to belong to the ‘sensori-motor 
loop’, which includes the post-commissural putamen 
rather than the ventral striatum [61]. Hence, our find-
ings are consistent with previous work in ASD demon-
strating atypical striatal FC with (pericentral) regions 
involved in vision and motor processing [26, 30, 57], 
and dysfunction in these domains [62–64]. The ante-
rior cingulate is implicated in emotional learning, the 
expression of emotional states [65], and self-regulation 
[66]. Together with the VSi, this region is thought to 
form part of a cortico-striatal ‘limbic loop’ that under-
pins emotion processing [61, 67]. Our findings of 
disruptions of this circuitry in ASD match previous 
reports of atypical fronto-striatal circuitry [26, 27] and 
emotion processing difficulties [68, 69] in this condi-
tion. A schematic of our findings in the context of the 
mentioned ‘loop’ systems can be found in Fig. 4.
For the sake of completeness, we also conducted sup-
plementary analyses delineating striatal baseline FC 
within each group separately. Our resulting findings pro-
vided a more detailed illustration of striatal FC patterns 
within each group. They further highlighted similarities 
and differences in FC profiles between groups, including 
those that were too underpowered to survive between-
group testing). As such, they are to be taken as purely 
descriptive.
Thus, our findings add to the existing literature by sug-
gesting that (1) in the adult autistic brain, the complex 
spatial organizational patterns of striatal FC along axes 
within/between subregions are disrupted. (2) These dis-
ruptions affect regions whose functions (e.g. cognitive, 
affective, associative, language/communication, or motor 
processing) are implicated in ASD symptoms [58, 62, 70, 
71]. Moreover, (3) these striatal systems were respon-
sive to pharmacological probing. A single dose of CBDV 
was sufficient to shift atypical striatal FC in the mature 
autistic brain towards the profile found at baseline in 
neurotypicals.
The precise neurobiological mechanisms underpinning 
the (differential) effects of CBDV on FC in the two groups 
are not clear. However, since CBDV has been shown to 
alter E–I balance in the basal ganglia [18] and the E–I 
system helps regulate FC [72–75], a shift in striatal E–I 
may contribute to a shift in striatal FC. In ASD, a wealth 
of studies suggests that E–I systems are altered [76–80]. 
This may help explain the differential effects of CBDV on 
E–I dependent FC. However, the striatum is a hub inte-
grating information from multiple neural regions, many 
of which may also possess targets for CBDV. Hence, we 
cannot exclude the possibility that at least some of our 
results derive from indirect action of CBDV on regions 
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Fig. 4 Reported findings in the context of cortico-striatal loop circuits. Baseline differences and group (ASD > neurotypicals) by drug (CBCV > PLC) 
interaction effects on cortico-striatal loop circuits, including the limbic and associative/cognitive loop, each of which are theorized to include 
different GPi/SNR and thalamic regions. Grey arrows indicate functional connections. ASD autism spectrum disorder, CBDV cannabidivarin, FC 
functional connectivity, GPi globus pallidus pars interna, L left, MD mediodorsal nucleus, PF parafascicular nucleus of the thalamus (dl: dorsolateral 
extension), R right, SNr substantia nigra pars reticulate, VA ventral anterior nucleus of the thalamus (mc: magnocellular part; pc: parvocellular part), 
VL ventrolateral nucleus of the thalamus (c: caudal part; m: medial part), vrP ventral-rostral putamen, VSi inferior ventral striatum. *The anterior 
paracentral lobule is associated with sensori-motor processing and may represent ectopic FC within the ‘limbic loop’ here
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connected with the striatum (e.g. substantia nigra, ven-
tral tegmentum, amygdala, frontal cortex, etc. [81]).
Notably, our study was not designed to determine 
the impact of CBDV on cognition or behaviour in ASD. 
However, we suggest that it is possible that the modu-
lation of striatal FC influences the cognitive functions 
supported by these pathways. Therefore, further exami-
nation of whether the biological impact of CBDV on 
brain is accompanied by, and/or predicts, a clinical 
response would be a useful next step. For instance, there 
is evidence from the valproic acid rat model that CBDV 
impacts on ASD-like behaviours [82]. Combined with the 
fact that CBDV has a low side effect profile (Investigator’s 
brochure for CBDV, Edition 4, May 2016), our findings 
may help develop the rationale for future clinical trials. 
However, our findings also add to a growing body of liter-
ature suggesting that the autistic brain may respond dif-
ferently to pharmacological probing [18, 83–86], and this 
should be considered in the development and testing of 
pharmacological interventions.
Limitations
Our findings should be viewed in light of several meth-
odological considerations. First, our sample size was 
relatively small. This was due to difficulties inherent to 
conducting pharmacological neuroimaging studies in 
ASD. For instance, these include the necessity to tol-
erate (mild) discomfort as well as the requirement to 
stay still during the scan, ingesting the pharmacological 
compound, navigating study procedures, the absence 
of medication that may interfere with the tested sub-
stance, and readiness to come back for follow-up visits. 
Nonetheless, we achieved an overall sample size similar 
to that reported in previous similar studies in ASD [52, 
87]. Second, to ensure sufficient power given our lim-
ited sample size, we examined a relatively homogeneous 
group of adult men. However, given that ASD is a neuro-
biologically heterogeneous condition, our findings should 
be considered as preliminary and may not ‘generalize’ to 
others. Future studies should therefore aim to study more 
heterogeneous samples, e.g. including children, women, 
and those with co-occurring conditions.
Third, we emphasize some important differences 
between previous approaches to examine FC in ASD, 
especially a recent large-scale analysis of whole-brain FC 
patterns in autistic and neurotypical individuals [88], and 
our study. Holiga and colleagues’ study was designed to 
map common baseline FC differences across whole brain 
in large numbers of people with(out) ASD. Conversely, 
our study was designed to investigate whether there are 
differences in the pharmacological response to CBDV in 
striatal FC. Further, Holiga et al. carried out a data-driven 
analysis of baseline FC using a degree centrality graph 
metric across the whole brain in children and adults, 
and males and females. In contrast, our study specifically 
aimed to examine FC of pre-specified regions of inter-
est using a different FC metric in a small, focused study 
limited to adult men. This approach precluded us from 
assessing whether the observed differences in FC (and its 
responsivity to pharmacological challenge) in ASD were 
limited to the striatum and its circuitry—or whether 
they extended to other regions/connections. Therefore, 
future studies into the effect of CBDV on whole-brain FC 
should examine larger groups that are suitably powered 
using data-driven approaches, and also apply alternative 
statistical tools, such as graph theory. Thus, the FC meas-
ures reported previously by Holiga et  al. and ours are 
not directly comparable. Fourth, this study examined the 
effect of acute CBDV manipulation. This was to estab-
lish proof of concept that CBDV can manipulate atypical 
striatal FC in the autistic and neurotypical adult brain. 
However, there may be a difference in brain response to 
a single dose compared to long-term (cannabinoid) phar-
macological probing [89, 90]. Accordingly, future studies 
should examine the effect of sustained CBDV challenge 
on brain, including striatal FC.
Conclusion
In conclusion, we identified atypicalities in striatal FC 
(both hyper- and hypoconnectivity) in adults with ASD. 
We also provided proof of concept that, in the adult 
autistic brain, atypical striatal circuitry can be shifted 
towards a more neurotypical pattern of FC through a 
single acute dose of CBDV. Future studies should exam-
ine whether this modulation of striatal FC in ASD affects 
cognition and behaviour.
Abbreviations
ASD: Autism spectrum disorder; CBD: Cannabidiol; CBDV: Cannabidivarin; 
CSF: Cerebrospinal fluid; DC: Dorsal caudate; dcP: Dorsal caudal putamen; drP: 
Dorsal rostral putamen; E–I: Excitation–inhibition; FC: Functional connectivity; 
GABA: Gamma amino butyric acid; GM: Grey matter; MNI: Montreal neurologi-
cal institute; PLC: Placebo; vrP: Ventral rostral putamen; VSi: Inferior ventral 
striatum; VSs: Superior ventral striatum; WM: White matter.
Supplementary Information
The online version contains supplementary material available at https:// doi. 
org/ 10. 1186/ s13229- 021- 00454-6.
Additional file 1. Figure S1. Placement of striatal seeds. Numbers 
above slices indicate Montreal Neurological Institute (MNI) z-coordinates. 
Abbreviations: A, anterior; DC, dorsal caudate; dcP, dorsal-caudal putamen; 
drP, dorsal-rostral putamen; I, inferior; L, left; P, posterior; R, right; ROI, 
region of interest; S, superior; vrP, ventral-rostral putamen; VSi, inferior 
ventral striatum; VSs, superior ventral striatum. Table S1. Between-group 
(ASD>neurotypicals) differences in striatal functional connectivity at 
baseline. Table displays statistics for targets (regions containing the cluster 
peak), including cluster size (in voxels), test statistics, and peak coordinates 
Page 12 of 14Pretzsch et al. Molecular Autism           (2021) 12:49 
in Montreal Neurological Institute (MNI) space (x,y,z). Abbreviations: 
d, Cohen’s d; L, left; R, right; ROI, region of interest; vrP, ventral-rostral 
putamen; VSi, inferior ventral striatum. Table S2. Interaction effect 
(ASD>neurotypicals, CBDV>PLC) on atypical baseline striatal functional 
connectivity. Abbreviations: d, Cohen’s d; L, left; R, right; vrP, ventral-rostral 
putamen; VSi, inferior ventral striatum.
Additional file 2. Table S3. Baseline striatal functional connectivity in the 
neurotypicals. Table displays statistics for targets (regions containing the 
cluster peak), including cluster size (in voxels), T-value (T-val), FDR-cor-
rected significance level (pFDR), and peak coordinates in Montreal Neuro-
logical Institute (MNI) space (x,y,z). Abbreviations: DC, dorsal caudate; dcP, 
dorsal-caudal putamen; drP, dorsal-rostral putamen; L, left; R, right; ROI, 
region of interest; vrP, ventralrostral putamen; VSi, inferior ventral striatum; 
VSs, superior ventral striatum. Table S4. Baseline striatal functional con-
nectivity in the ASD group. Table displays statistics for targets (regions 
containing the cluster peak), including cluster size (in voxels), T-value 
(T-val), FDR-corrected significance level (pFDR), and peak coordinates 
in Montreal Neurological Institute (MNI) space (x,y,z). Abbreviations: DC, 
dorsal caudate; dcP, dorsal-caudal putamen; drP, dorsal-rostral putamen; L, 
left; R, right; ROI, region of interest; vrP, ventralrostral putamen; VSi, inferior 
ventral striatum; VSs, superior ventral striatum.
Acknowledgements
The authors sincerely thank all the participants. Thank you also to ABI for 
continuous, unwavering support.  
Authors’ contributions
C.M.P., D.G.M.M., and G.M.M. developed the theoretical framework. C.M.P., D.L.F., 
and B.V. implemented the research with support from M.E., M.A.M., R.W., L.A., 
G.I., M.H., S.W., D.G.M.M., E.D., and G.M.M. C.M.P., D.G.M.M., and G.M.M. wrote the 
article with aid in the interpretation of findings from D.L.F., E.P., and E.D., and 
input from all authors on the manuscript. All authors read and approved the 
final manuscript.
Funding
This study was an Investigator Initiated Study (G.M.) which received funding 
and product from GW Research Ltd (Cambridge, UK). GW Research Ltd (Cam-
bridge, UK) had no role in the data collection or analysis of results, nor in the 
decision to publish. The authors also acknowledge infrastructure and training 
support from the National Institute for Health Research (NIHR) Mental Health 
Biomedical Research Centre (BRC) at the South London and Maudsley NHS 
Foundation Trust and King’s College London. The views expressed are those of 
the authors and not necessarily those of the NHS, the NIHR or the Department 
of Health, UK. Moreover, the results leading to this publication have received 
funding from the Innovative Medicines Initiative 2 Joint Undertaking under 
Grant Agreement No. 777394 for the project AIMS-2-TRIALS. This Joint Under-
taking receives support from the European Union’s Horizon 2020 research and 
innovation programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI. The 
views expressed are those of the author(s) and not necessarily those of the IMI 
2JU. Additional sources of support included the Sackler Institute for Transla-
tional Neurodevelopment at King’s College London, Autistica, and a Medical 
Research Council (MRC) Centre Grant (MR/N026063/1).
Availability of data and materials
The datasets used and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Declarations
Ethics approval and consent to participate
The King’s College London Research Ethics Committee provided institutional 
ethical approval for this study (reference HR15/162744). All participants pro-




The authors declare that they have no competing interests.
Author details
1 Department of Forensic and Neurodevelopmental Sciences, Institute 
of Psychiatry, Psychology and Neuroscience, King’s College London, 16 De 
Crespigny Park, London SE5 8AF, UK. 2 Department of Cognitive Neuroscience, 
Donders Institute for Brain, Cognition and Behaviour, Radboud University 
Nijmegen Medical Centre, Nijmegen, The Netherlands. 3 Department of Liaison 
Psychiatry, Bristol Royal Infirmary, University Hospitals Bristol and Weston NHS 
Foundation Trust, Bristol, UK. 4 Instituto de Investigación Sanitaria Gregorio 
Marañón, Madrid, Spain. 5 Department of Psychiatry GGZ Geest, Amsterdam, 
The Netherlands. 6 Medicines Discovery Catapult, Alderley Park, Alderley 
Edge SK10 4TG, Cheshire, UK. 7 South London and Maudsley NHS Foundation 
Trust Pharmacy, London, UK. 8 Department of General, Visceral, and Transplant 
Surgery, Ludwig-Maximilians-University Munich, Munich, Germany. 9 Depart-
ment of Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neu-
roscience, King’s College London, London, UK. 
Received: 8 February 2021   Accepted: 17 June 2021
References
 1. American Psychiatric Association. Diagnostic and statistical manual of 
mental disorders. DSM-5, 5th edn. In: American Psychiatric Association, 
editor. Washington, DC: American Psychiatric Association; 2013.
 2. Miller M, Chukoskie L, Zinni M, Townsend J, Trauner D. Dyspraxia, motor 
function and visual-motor integration in autism. Behav Brain Res. 
2014;269:95–102.
 3. Scott-Van Zeeland AA, Dapretto M, Ghahremani DG, Poldrack 
RA, Bookheimer SY. Reward processing in autism. Autism Res. 
2010;3(2):53–67.
 4. Hill EL. Executive dysfunction in autism. Trends Cogn Sci. 
2004;8(1):26–32.
 5. Simonoff E, Jones CR, Pickles A, Happe F, Baird G, Charman T. Severe 
mood problems in adolescents with autism spectrum disorder. J Child 
Psychol Psychiatry. 2012;53(11):1157–66.
 6. Mazefsky CA, Herrington J, Siegel M, Scarpa A, Maddox BB, Scahill L, 
et al. The role of emotion regulation in autism spectrum disorder. J Am 
Acad Child Adolesc Psychiatry. 2013;52(7):679–88.
 7. Cadman T, Eklund H, Howley D, Hayward H, Clarke H, Findon J, et al. 
Caregiver burden as people with autism spectrum disorder and 
attention-deficit/hyperactivity disorder transition into adolescence 
and adulthood in the United Kingdom. J Am Acad Child Psychiatry. 
2012;51(9):879–88.
 8. Leigh JP, Du J. Brief report: forecasting the economic burden of 
autism in 2015 and 2025 in the United States. J Autism Dev Disord. 
2015;45(12):4135–9.
 9. van Heijst BF, Geurts HM. Quality of life in autism across the lifespan: a 
meta-analysis. Autism. 2015;19(2):158–67.
 10. Fuccillo MV. Striatal circuits as a common node for autism pathophysiol-
ogy. Front Neurosci. 2016;10:27.
 11. Bhanji JP, Delgado MR. The social brain and reward: social informa-
tion processing in the human striatum. Wiley Interdiscip Rev Cogn Sci. 
2014;5(1):61–73.
 12. Gerardin E, Pochon JB, Poline JB, Tremblay L, Van de Moortele PF, Levy R, 
et al. Distinct striatal regions support movement selection, preparation 
and execution. NeuroReport. 2004;15(15):2327–31.
 13. Di Martino A, Scheres A, Margulies DS, Kelly AM, Uddin LQ, Shehzad Z, 
et al. Functional connectivity of human striatum: a resting state FMRI 
study. Cereb Cortex. 2008;18(12):2735–47.
 14. Parent A, Hazrati LN. Functional anatomy of the basal ganglia. I. The 
cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev. 
1995;20(1):91–127.
 15. Postuma RB, Dagher A. Basal ganglia functional connectivity based 
on a meta-analysis of 126 positron emission tomography and func-
tional magnetic resonance imaging publications. Cereb Cortex. 
2006;16(10):1508–21.
Page 13 of 14Pretzsch et al. Molecular Autism           (2021) 12:49  
 16. Barber AD, Sarpal DK, John M, Fales CL, Mostofsky SH, Malhotra AK, et al. 
Age-normative pathways of striatal connectivity related to clinical symp-
toms in the general population. Biol Psychiatry. 2019;85(11):966–76.
 17. Pretzsch CM, Freyberg J, Voinescu B, Lythgoe D, Horder J, Mendez MA, 
et al. Effects of cannabidiol on brain excitation and inhibition systems; 
a randomised placebo-controlled single dose trial during magnetic 
resonance spectroscopy in adults with and without autism spectrum 
disorder. Neuropsychopharmacology. 2019;44(8):1398–405.
 18. Pretzsch CM, Voinescu B, Lythgoe D, Horder J, Mendez MA, Wichers R, 
et al. Effects of cannabidivarin (CBDV) on brain excitation and inhibition 
systems in adults with and without Autism Spectrum Disorder (ASD): a 
single dose trial during magnetic resonance spectroscopy. Transl Psychia-
try. 2019;9(1):313.
 19. Hassan TH, Abdelrahman HM, Fattah NRA, El-Masry NM, Hashim HM, El-
Gerby KM, et al. Blood and brain glutamate levels in children with autistic 
disorder. Res Autism Spectr Dis. 2013;7(4):541–8.
 20. Shafritz KM, Dichter GS, Baranek GT, Belger A. The neural circuitry 
mediating shifts in behavioral response and cognitive set in autism. Biol 
Psychiatry. 2008;63(10):974–80.
 21. Delmonte S, Balsters JH, McGrath J, Fitzgerald J, Brennan S, Fagan AJ, et al. 
Social and monetary reward processing in autism spectrum disorders. 
Mol Autism. 2012;3(1):7.
 22. Stanfield AC, McIntosh AM, Spencer MD, Philip R, Gaur S, Lawrie SM. 
Towards a neuroanatomy of autism: a systematic review and meta-
analysis of structural magnetic resonance imaging studies. Eur Psychiatry. 
2008;23(4):289–99.
 23. Hollander E, Anagnostou E, Chaplin W, Esposito K, Haznedar MM, Licalzi 
E, et al. Striatal volume on magnetic resonance imaging and repetitive 
behaviors in autism. Biol Psychiatry. 2005;58(3):226–32.
 24. Langen M, Durston S, Staal WG, Palmen SJ, van Engeland H. Caudate 
nucleus is enlarged in high-functioning medication-naive subjects with 
autism. Biol Psychiatry. 2007;62(3):262–6.
 25. Pote I, Wang S, Sethna V, Blasi A, Daly E, Kuklisova-Murgasova M, et al. 
Familial risk of autism alters subcortical and cerebellar brain anatomy in 
infants and predicts the emergence of repetitive behaviors in early child-
hood. Autism Res. 2019;12(4):614–27.
 26. Maximo JO, Kana RK. Aberrant “deep connectivity” in autism: a cortico-
subcortical functional connectivity magnetic resonance imaging study. 
Autism Res. 2019;12(3):384–400.
 27. Delmonte S, Gallagher L, O’Hanlon E, McGrath J, Balsters JH. Functional 
and structural connectivity of frontostriatal circuitry in Autism Spectrum 
Disorder. Front Hum Neurosci. 2013;7:430.
 28. Lynch CJ, Uddin LQ, Supekar K, Khouzam A, Phillips J, Menon V. Default 
mode network in childhood autism: posteromedial cortex heterogeneity 
and relationship with social deficits. Biol Psychiatry. 2013;74(3):212–9.
 29. Padmanabhan A, Lynn A, Foran W, Luna B, O’Hearn K. Age related 
changes in striatal resting state functional connectivity in autism. Front 
Hum Neurosci. 2013;7:814.
 30. Cerliani L, Mennes M, Thomas RM, Di Martino A, Thioux M, Keysers C. 
Increased Functional connectivity between subcortical and cortical 
resting-state networks in autism spectrum disorder. JAMA Psychiat. 
2015;72(8):767–77.
 31. Fox MD, Raichle ME. Spontaneous fluctuations in brain activity observed 
with functional magnetic resonance imaging. Nat Rev Neurosci. 
2007;8(9):700–11.
 32. Di Martino A, Kelly C, Grzadzinski R, Zuo XN, Mennes M, Mairena MA, 
et al. Aberrant striatal functional connectivity in children with autism. Biol 
Psychiatry. 2011;69(9):847–56.
 33. Stagg CJ, Bachtiar V, Amadi U, Gudberg CA, Ilie AS, Sampaio-Baptista C, 
et al. Local GABA concentration is related to network-level resting func-
tional connectivity. Elife. 2014;3:e01465.
 34. Vattikonda A, Surampudi BR, Banerjee A, Deco G, Roy D. Does the regula-
tion of local excitation-inhibition balance aid in recovery of functional 
connectivity? A computational account. Neuroimage. 2016;136:57–67.
 35. Gu H, Hu Y, Chen X, He Y, Yang Y. Regional excitation–inhibition balance 
predicts default-mode network deactivation via functional connectivity. 
Neuroimage. 2019;185:388–97.
 36. Iannotti FA, Hill CL, Leo A, Alhusaini A, Soubrane C, Mazzarella E, et al. 
Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and can-
nabidiol (CBD), activate and desensitize transient receptor potential 
vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of 
neuronal hyperexcitability. ACS Chem Neurosci. 2014;5(11):1131–41.
 37. Gibson HE, Edwards JG, Page RS, Van Hook MJ, Kauer JA. TRPV1 channels 
mediate long-term depression at synapses on hippocampal interneu-
rons. Neuron. 2008;57(5):746–59.
 38. Miyake T, Shirakawa H, Nakagawa T, Kaneko S. Activation of mitochondrial 
transient receptor potential vanilloid 1 channel contributes to microglial 
migration. Glia. 2015;63(10):1870–82.
 39. Cristino L, de Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V. 
Immunohistochemical localization of cannabinoid type 1 and vanilloid 
transient receptor potential vanilloid type 1 receptors in the mouse brain. 
Neuroscience. 2006;139(4):1405–15.
 40. Kunert-Keil C, Bisping F, Kruger J, Brinkmeier H. Tissue-specific expres-
sion of TRP channel genes in the mouse and its variation in three 
different mouse strains. BMC Genomics. 2006. https:// doi. org/ 10. 1186/ 
1471- 2164-7- 159.
 41. Bhattacharyya S, Falkenberg I, Martin-Santos R, Atakan Z, Crippa JA, 
Giampietro V, et al. Cannabinoid modulation of functional connectivity 
within regions processing attentional salience. Neuropsychopharmacol-
ogy. 2015;40(6):1343–52.
 42. Lord C. Autism diagnostic observation schedule: a standardized 
observation of communicative and social behavior. J Autism Dev Disord. 
1989;19(2):185–212.
 43. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: 
a revised version of a diagnostic interview for caregivers of individuals 
with possible pervasive developmental disorders. J Autism Dev Disord. 
1994;24(5):659–85.
 44. World Health Organisation. International statistical classification of 
diseases and related health problems. Geneva: WHO; 2016.
 45. Whitfield-Gabrieli S, Nieto-Castanon A. Conn: a functional connectivity 
toolbox for correlated and anticorrelated brain networks. Brain Con-
nect. 2012;2(3):125–41.
 46. Redcay E, Moran JM, Mavros PL, Tager-Flusberg H, Gabrieli JD, 
Whitfield-Gabrieli S. Intrinsic functional network organization in high-
functioning adolescents with autism spectrum disorder. Front Hum 
Neurosci. 2013;7:573.
 47. Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE. Spurious 
but systematic correlations in functional connectivity MRI networks 
arise from subject motion. Neuroimage. 2012;59(3):2142–54.
 48. Alexander GE, DeLong MR, Strick PL. Parallel organization of function-
ally segregated circuits linking basal ganglia and cortex. Annu Rev 
Neurosci. 1986;9:357–81.
 49. Floris DL, Barber AD, Nebel MB, Martinelli M, Lai MC, Crocetti D, et al. 
Atypical lateralization of motor circuit functional connectivity in 
children with autism is associated with motor deficits. Mol Autism. 
2016;7:35.
 50. Nielsen JA, Zielinski BA, Fletcher PT, Alexander AL, Lange N, Bigler 
ED, et al. Abnormal lateralization of functional connectivity between 
language and default mode regions in autism. Mol Autism. 2014;5(1):8.
 51. Friston KJ, Worsley KJ, Frackowiak RS, Mazziotta JC, Evans AC. Assessing 
the significance of focal activations using their spatial extent. Hum 
Brain Mapp. 1994;1(3):210–20.
 52. Grimm O, Loffler M, Kamping S, Hartmann A, Rohleder C, Leweke M, 
et al. Probing the endocannabinoid system in healthy volunteers: can-
nabidiol alters fronto-striatal resting-state connectivity. Eur Neuropsy-
chopharmacol. 2018;28:841–9.
 53. O’Neill A, Wilson R, Blest-Hopley G, Annibale L, Colizzi M, Brammer 
M, et al. Normalization of mediotemporal and prefrontal activity, and 
mediotemporal-striatal connectivity, may underlie antipsychotic 
effects of cannabidiol in psychosis. Psychol Med. 2020;51:596–606.
 54. Just MA, Cherkassky VL, Keller TA, Minshew NJ. Cortical activation and 
synchronization during sentence comprehension in high-functioning 
autism: evidence of underconnectivity. Brain. 2004;127(Pt 8):1811–21.
 55. Howard MA, Volkov IO, Mirsky R, Garell PC, Noh MD, Granner M, et al. 
Auditory cortex on the human posterior superior temporal gyrus. J 
Comp Neurol. 2000;416(1):79–92.
 56. Chang EF, Rieger JW, Johnson K, Berger MS, Barbaro NM, Knight RT. 
Categorical speech representation in human superior temporal gyrus. 
Nat Neurosci. 2010;13(11):1428–32.
Page 14 of 14Pretzsch et al. Molecular Autism           (2021) 12:49 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 57. Turner KC, Frost L, Linsenbardt D, McIlroy JR, Muller RA. Atypically 
diffuse functional connectivity between caudate nuclei and cerebral 
cortex in autism. Behav Brain Funct. 2006;2:34.
 58. Nikolaenko NN. Metaphorical and associative thinking in healthy chil-
dren and in children with Asperger’s syndrome at different ages. Fiziol 
Cheloveka. 2004;30(5):36–40.
 59. Lim SH, Dinner DS, Pillay PK, Luders H, Morris HH, Klem G, et al. 
Functional anatomy of the human supplementary sensorimotor area: 
results of extraoperative electrical stimulation. Electroencephalogr Clin 
Neurophysiol. 1994;91(3):179–93.
 60. Yang H, Long XY, Yang Y, Yan H, Zhu CZ, Zhou XP, et al. Amplitude of 
low frequency fluctuation within visual areas revealed by resting-state 
functional MRI. Neuroimage. 2007;36(1):144–52.
 61. Alexander GE, Crutcher MD, DeLong MR. Basal ganglia-thalamocortical 
circuits: parallel substrates for motor, oculomotor, “prefrontal” and 
“limbic” functions. Prog Brain Res. 1990;85:119–46.
 62. Hardan AY, Kilpatrick M, Keshavan MS, Minshew NJ. Motor performance 
and anatomic magnetic resonance imaging (MRI) of the basal ganglia 
in autism. J Child Neurol. 2003;18(5):317–24.
 63. Muller RA, Pierce K, Ambrose JB, Allen G, Courchesne E. Atypical pat-
terns of cerebral motor activation in autism: a functional magnetic 
resonance study. Biol Psychiatry. 2001;49(8):665–76.
 64. Sachse M, Schlitt S, Hainz D, Ciaramidaro A, Schirman S, Walter H, et al. 
Executive and visuo-motor function in adolescents and adults with 
autism spectrum disorder. J Autism Dev Disord. 2013;43(5):1222–35.
 65. Devinsky O, Morrell MJ, Vogt BA. Contributions of anterior cingulate 
cortex to behaviour. Brain. 1995;118(Pt 1):279–306.
 66. Posner MI, Rothbart MK, Sheese BE, Tang Y. The anterior cingulate gyrus 
and the mechanism of self-regulation. Cogn Affect Behav Neurosci. 
2007;7(4):391–5.
 67. Galvan A, Devergnas A, Wichmann T. Alterations in neuronal activity in 
basal ganglia-thalamocortical circuits in the Parkinsonian state. Front 
Neuroanat. 2015;9:5.
 68. Bal E, Harden E, Lamb D, Van Hecke AV, Denver JW, Porges SW. Emotion 
recognition in children with autism spectrum disorders: relations to eye 
gaze and autonomic state. J Autism Dev Disord. 2010;40(3):358–70.
 69. Samson AC, Huber O, Gross JJ. Emotion regulation in Asperger’s syn-
drome and high-functioning autism. Emotion. 2012;12(4):659–65.
 70. Baron-Cohen S. Social and pragmatic deficits in autism: cognitive or 
affective? J Autism Dev Disord. 1988;18(3):379–402.
 71. Howlin P, Goode S, Hutton J, Rutter M. Adult outcome for children with 
autism. J Child Psychol Psychiatry. 2004;45(2):212–29.
 72. Bachtiar V, Near J, Johansen-Berg H, Stagg CJ. Modulation of GABA and 
resting state functional connectivity by transcranial direct current stimu-
lation. Elife. 2015;4:e08789.
 73. Stagg CJ, Bachtiar V, Amadi U, Gudberg CA, Ilie AS, Sampaio-Baptista C, 
et al. Local GABA concentration is related to network-level resting func-
tional connectivity. Elife. 2014. https:// doi. org/ 10. 7554/ eLife. 01465.
 74. Kwon SH, Scheinost D, Lacadie C, Benjamin J, Myers EH, Qiu M, et al. 
GABA, resting-state connectivity and the developing brain. Neonatology. 
2014;106(2):149–55.
 75. Kapogiannis D, Reiter DA, Willette AA, Mattson MP. Posteromedial cortex 
glutamate and GABA predict intrinsic functional connectivity of the 
default mode network. Neuroimage. 2013;64:112–9.
 76. Ajram LA, Pereira AC, Durieux AMS, Velthius HE, Petrinovic MM, McAlonan 
GM. The contribution of [1H] magnetic resonance spectroscopy to the 
study of excitation-inhibition in autism. Prog Neuropsychopharmacol Biol 
Psychiatry. 2018;89:236–44.
 77. Antoine MW, Langberg T, Schnepel P, Feldman DE. Increased excitation–
inhibition ratio stabilizes synapse and circuit excitability in four autism 
mouse models. Neuron. 2019;78:510.
 78. Nelson SB, Valakh V. Excitatory/inhibitory balance and circuit homeostasis 
in autism spectrum disorders. Neuron. 2015;87(4):684–98.
 79. Robertson CE, Ratai EM, Kanwisher N. Reduced GABAergic action in the 
autistic brain. Curr Biol. 2016;26(1):80–5.
 80. Rubenstein JL, Merzenich MM. Model of autism: increased ratio 
of excitation/inhibition in key neural systems. Genes Brain Behav. 
2003;2(5):255–67.
 81. Robbins TW, Everitt BJ, editors. Functions of dopamine in the dorsal and 
ventral striatum. Seminars in neuroscience. Amsterdam: Elsevier; 1992.
 82. Zamberletti E, Gabaglio M, Woolley-Roberts M, Bingham S, Rubino T, 
Parolaro D. Cannabidivarin treatment ameliorates autism-like behaviors 
and restores hippocampal endocannabinoid system and glia alterations 
induced by prenatal valproic acid exposure in rats. Front Cell Neurosci. 
2019;13:367.
 83. Gordon I, Jack A, Pretzsch CM, Vander Wyk B, Leckman JF, Feldman R, et al. 
Intranasal oxytocin enhances connectivity in the neural circuitry support-
ing social motivation and social perception in children with autism. Sci 
Rep. 2016;6:35054.
 84. Pretzsch CM, Freyberg J, Voinescu B, Lythgoe D, Horder J, Mendez MA, 
et al. Effects of cannabidiol on brain excitation and inhibition systems; 
a randomised placebo-controlled single dose trial during magnetic 
resonance spectroscopy in adults with and without autism spectrum 
disorder. Neuropsychopharmacology. 2019;44:1398–405.
 85. Pretzsch CM, Voinescu B, Mendez MA, Wichers R, Ajram L, Ivin G, et al. 
The effect of cannabidiol (CBD) on low-frequency activity and functional 
connectivity in the brain of adults with and without autism spectrum 
disorder (ASD). J Psychopharmacol. 2019;33:1141–8.
 86. Ajram LA, Horder J, Mendez MA, Galanopoulos A, Brennan LP, Wichers RH, 
et al. Shifting brain inhibitory balance and connectivity of the prefron-
tal cortex of adults with autism spectrum disorder. Transl Psychiatry. 
2017;7(5):e1137.
 87. Gordon I, Vander Wyk BC, Bennett RH, Cordeaux C, Lucas MV, Eilbott JA, 
et al. Oxytocin enhances brain function in children with autism. Proc Natl 
Acad Sci USA. 2013;110(52):20953–8.
 88. Holiga S, Hipp JF, Chatham CH, Garces P, Spooren W, D’Ardhuy XL, et al. 
Patients with autism spectrum disorders display reproducible functional 
connectivity alterations. Sci Transl Med. 2019;11(481):eaat9223.
 89. Haddjeri N, Blier P, de Montigny C. Acute and long-term actions of the 
antidepressant drug mirtazapine on central 5-HT neurotransmission. J 
Affect Disord. 1998;51(3):255–66.
 90. Nakamura EM, da Silva EA, Concilio GV, Wilkinson DA, Masur J. Revers-
ible effects of acute and long-term administration of delta-9-tetrahy-
drocannabinol (THC) on memory in the rat. Drug Alcohol Depend. 
1991;28(2):167–75.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
